UPDATE: Morgan Stanley Upgrades argenx SE (ARGX) to Overweight on Expectations for Vyvgart Upside

May 3, 2022 3:29 AM EDT
Get Alerts ARGX Hot Sheet
Price: $389.84 +4.28%

Rating Summary:
    16 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 12 | Down: 16 | New: 15
Join SI Premium – FREE
(Updated - May 3, 2022 7:45 AM EDT)

Morgan Stanley analyst Matthew Harrison upgraded argenx SE (NASDAQ: ARGX) from Equalweight to Overweight with a price target of $375.00 (from $278.00) on the belief that the Vyvgart launch in gMG should perform better than expected, driving upside in 2022.

The analyst stated "Based on our analysis of consensus revenue expectations and conversations with physicians, we believe Vyvgart is launching well. We expect a beat in 1Q and favorable patient dynamics for 2022. Overall, consensus expects lower patient numbers in the first two quarters of launch as compared to Soliris (1Q+2Q: 277 Cons v.s. 332 Soliris), but given the broader market and robust physician uptake commentary, we see the potential to outperform."

For an analyst ratings summary and ratings history on argenx SE click here. For more ratings news on argenx SE click here.

Shares of argenx SE closed at $293.35 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Upgrades

Related Entities

Morgan Stanley